Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$1.94−0.10 (-4.90%)
Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –
Niagen Bioscience pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Niagen Bioscience's pe ratio was 11.6× on Nov 11, 2026, against 28.2× a year earlier. Over the last 2 years it ranged from 11.6× to 772.0×, with a median of 28.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 11.6× | −14.9 |
| 2025 | Dec 31, 2025 | 26.5× | −504.0 |
| 2024 | Dec 31, 2024 | 530.5× | – |
See a number that looks wrong?